Africa Novel Antibiotics Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Infection, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Africa · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$113.8 MnPlaceholder estimate
Estimate 2025$121.2 Mn1.5% of the global market
Projected 2034$213.7 Mn 76.3%Adds $92.5 Mn over 9 forecast years
CAGR 2025–20346.5%Faster than 17% of 180 Pharmaceuticals markets here
Key players5
Africa is 1.47% of the global market.
Among regions, the largest is North America at $4.41 Bn.
Fastest growing: Africa (this report) at 6.5% a year.
Africa ranks 6th of 6 by size among regions.
Market size projection
Africa
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$92.5 Mn total, 2026–2034
Year-by-year market size, 2024–2034
Novel Antibiotics Market market size by year, Africa
Year
Market size
Change that year
Since 2025
2024 (estimate)
$113.8 Mn
—
—
2025 (base)
$121.2 Mn
+$7.4 Mn
—
2026 (forecast)
$129.1 Mn
+$7.9 Mn
+6.5%
2027 (forecast)
$137.5 Mn
+$8.4 Mn
+13.4%
2028 (forecast)
$146.5 Mn
+$8.9 Mn
+20.8%
2029 (forecast)
$156.0 Mn
+$9.5 Mn
+28.6%
2030 (forecast)
$166.1 Mn
+$10.1 Mn
+37%
2031 (forecast)
$176.9 Mn
+$10.8 Mn
+45.9%
2032 (forecast)
$188.4 Mn
+$11.5 Mn
+55.4%
2033 (forecast)
$200.7 Mn
+$12.2 Mn
+65.5%
2034 (forecast)
$213.7 Mn
+$13.0 Mn
+76.3%
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
13 in AfricaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Africa Novel Antibiotics Market Analysis Executive Summary
Novel antibiotics are new antibacterial drugs designed to treat infections caused by bacteria resistant to existing medicines.
Key segments of the novel Antibiotics market include drug class (Beta-Lactam Combinations, Novel Classes and Antibody Therapies) and infection (Gram-Negative, Gram-Positive and C. difficile).
Africa Novel Antibiotics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Africa Novel Antibiotics Market Dynamics
Market Growth Drivers
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the novel Antibiotics market.
Opportunity
New vaccines, rapid tests and public-private funding for neglected diseases give the novel Antibiotics market room to grow, especially in Asia, Africa and Latin America.
Market Restraints
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the novel Antibiotics market.
Competitive Landscape for Novel Antibiotics Market in Africa
The novel Antibiotics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Novel Antibiotics Market in Africa
Novel Antibiotics in Africa: rules, payment and research
The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together.[1] In some of the countries we cover here, medicines are approved by EDA (Egypt)[2], PPB (Kenya)[3] and SAHPRA (South Africa)[4]. How care is paid for in some of these countries: universal health insurance (Egypt)[5], the SHA (Kenya)[6] and planned National Health Insurance (South Africa)[7]. ClinicalTrials.gov lists 13 studies on Novel Antibiotics that are recruiting, active or about to start in Africa.[8]
[8]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for novel Antibiotics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Africa.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug Class
4.2 By Infection
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Pfizer
7.2 Shionogi
7.3 Merck & Co.
7.4 Innoviva Specialty Therapeutics
7.5 Venatorx Pharmaceuticals
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The novel Antibiotics market can be segmented based on various criteria, including drug class, infection and end user. Here's a breakdown of the market segmentation
What doctors and scientists are doing in Novel Antibiotics right now, from free public sources.
Clinical trials
13 active trials in Egypt, South Africa, Kenya, Nigeria, Ethiopia, DR Congo, Uganda, Tanzania, Niger, Mozambique, Sudan, Malawi, Zambia, Mali, Burkina Faso, Ghana and Morocco
Recruiting, about to start, or running now. Counted across the 17 countries we report on in Africa.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Novel Antibiotics market in Africa?
Placeholder estimate: about $121.2 Mn in 2025, rising to about $213.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Novel Antibiotics market in Africa growing?
Placeholder estimate: about 6.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Novel Antibiotics market report cover?
The report splits the market by drug class (Beta-Lactam Combinations, Novel Classes, Antibody Therapies, Phage Therapy), infection (Gram-Negative, Gram-Positive, C. difficile, Tuberculosis) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Novel Antibiotics market?
Key players include Pfizer Inc., Shionogi, Merck & Co., Inc., Innoviva Specialty Therapeutics and Venatorx Pharmaceuticals.
What is driving the Novel Antibiotics market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the novel Antibiotics market.
Who regulates Novel Antibiotics in Africa?
The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together. Source: African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
How many clinical trials on Novel Antibiotics are running in Africa?
13 studies are recruiting, active or about to start in Africa, counted across the 17 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
How much research is published on Novel Antibiotics?
PubMed lists 914 papers on Novel Antibiotics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.